David W. Boulton - Concepedia

Author

David W. Boulton

Bristol-Myers Squibb (United States)ORCID

Also Known As

Boulton, David W., D BOULTON, D Boulton, D W Boulton, D. Boulton, D. W. BOULTON, D. W. Boulton, D.W. Boulton, DAVID W. BOULTON, David Boulton

193

Publications

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)AstraZeneca (United States)Bristol-Myers Squibb (Germany)AstraZeneca (Sweden)Medical University of South Carolina

About

David W. Boulton is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	35	2.1K
2	Allergy	2	2	74
3	Engineering	1	1	44
4	Health Sciences	1	1	108
5	Social Sciences	1	1	65

David W. Boulton

Publications

Citations

H-Index

Page 1

	Year	Citations
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes Mark C. Petrie, Subodh Verma, Kieran F. Docherty, JAMA	2020	516
Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis Karen Melissa Hallow, Gabriel Helmlinger, Peter J. Greasley, Diabetes Obesity and Metabolism Molecular PharmacologyHeart Failure HospitalizationHeart FailureCardiovascular DiseaseMedicine	2017	459
Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects Bernard J. Komoroski, N. Vachharajani, David W. Boulton, Clinical Pharmacology & Therapeutics	2009	342
Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes Ralph A. DeFronzo, Marcus Hompesch, Sreeneeranj Kasichayanula, Diabetes Care	2013	281
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics David W. Boulton, C. Lindsay DeVane, Heidi L. Liston, Life Sciences PsychiatryMedicinePsychotropic MedicationPsychopharmacologyPharmacotherapy	2002	259
Extensive Binding of the Bioflavonoid Quercetin to Human Plasma Proteins David W. Boulton, U. Kristina Walle, Thomas Walle Journal of Pharmacy and Pharmacology	1998	208
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF Alice M. Jackson, Pooja Dewan, Inder S. Anand, Circulation	2020	169
Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers John S. Markowitz, C. Lindsay DeVane, David W. Boulton, Life Sciences St. JohnBiochemistryMedicineHealthy VolunteersPhysiology	2000	145
Interaction Between the Sodium‐Glucose–Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects Christopher S. Wilcox, Wen Shen, David W. Boulton, Journal of the American Heart Association	2018	132
Fate of the Flavonoid Quercetin in Human Cell Lines: Chemical Instability and Metabolism David W. Boulton, U. Kristina Walle, Thomas Walle Journal of Pharmacy and Pharmacology	1999	125

Page 1